



# Pneumosil

Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed, 10-Valent)

## Relevant Serotypes, Comprehensive Protection

A Tailored PCV for Developing Countries with 6A and 19A - "Affordable Protection"

## WHO Pre-Qualified

### **PNEUMOSIL® – The new pneumococcal vaccine from Serum Institute of India achieves WHO prequalification**

We take this opportunity to introduce PNEUMOSIL® (Pneumococcal Conjugate Vaccine - adsorbed, 10 Valent), a well-designed vaccine with relevant serotypes yet more affordable than existing PCVs and provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries.

As a PCV PNEUMOSIL® is the same kind of vaccine as the paediatric pneumococcal vaccine already on the market and targets serotypes 1,5,6A,6B,7F,9V,14,19A,19F,23F.

PNEUMOSIL® is now **WHO pre-qualified** for its procurement by United Nations Agencies and GAVI. This marks an important milestone towards accelerated access of this **much needed affordable vaccine** for the countries with high disease burden.

PNEUMOSIL® developed through a collaboration spanning over a decade between Serum Institute of India Pvt Ltd and PATH and with funding from Bill and Melinda Gates foundation. Through the collaboration, the vaccine has advanced from preclinical and clinical development to WHO pre-qualification.

PNEUMOSIL® safety and immunogenicity profile is favourably comparable to both currently available licensed and WHO pre-qualified PCVs worldwide. Various seroprevalence assessment estimates PNEUMOSIL® serotype coverage similar to other PCVs in high disease burden countries including countries with high seroprevalence of 6A and 19A.

#### **PNEUMOSIL® is here! Why this matters? Why price is so important?**

Each year nearly 400,000 children under 5 years of age die globally from pneumococcal diseases,<sup>1</sup> mostly in Africa, Asia and LATAM Region. WHO pre-qualification opens the door for this vaccine being accessible that countries can **afford and sustain** their pneumococcal immunization programme.

We would welcome the opportunity to present the extensively compiled data of PNEUMOSIL® for a meaningful consideration of PNEUMOSIL® as a potential choice for your PCV immunization programme.

We look forward to hearing from you.



## SERUM INSTITUTE OF INDIA

CYRUS POONAWALLA GROUP

212/2 Hadapsar, Pune 411 028, India. Tel.: +91 20 26993900/04 Fax: +91 20 26993924.  
website: [www.seruminstitute.com](http://www.seruminstitute.com) E-mail: [exports@seruminstitute.com](mailto:exports@seruminstitute.com)

1: <https://www.path.org/articles/new-pneumococcal-vaccine/>